Browsing Tag
ASCVD
4 posts
Merck’s enlicitide slashes LDL-C by 55.8%: Could this daily pill replace PCSK9 injections?
Merck’s enlicitide cuts LDL-C by over 55% in Phase 3 trial. Could it become the first oral PCSK9 inhibitor to transform ASCVD treatment?
Why is Novartis acquiring Tourmaline Bio—and how does pacibekitug fit into its cardiovascular pipeline?
Novartis is acquiring Tourmaline Bio in a $1.4B deal to advance pacibekitug, a promising anti-IL-6 therapy for atherosclerotic cardiovascular disease.
Novartis gets Leqvio FDA approval for reducing bad cholesterol levels
Novartis has secured approval from the US Food and Drug Administration (FDA) for its small interfering RNA (siRNA)…
Regeneron and Sanofi’s Praluent gets European approval for reducing cardiovascular risk in atherosclerotic disease patients
Regeneron Pharmaceuticals and Sanofi have received a significant boost with the European Commission’s (EC) approval of Praluent (alirocumab)…